Suppr超能文献

体外药代动力学模型中莫西沙星对肺炎链球菌和铜绿假单胞菌的活性及耐药性的产生

Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.

作者信息

MacGowan Alasdair P, Rogers Chris A, Holt H Alan, Bowker Karen E

机构信息

Bristol Centre for Antimicrobial Research and Evaluation, University of Bristol and North Bristol NHS Trust, Department of Medical Microbiology, Southmead Hospital, Westbury-on-Trym, United Kingdom.

出版信息

Antimicrob Agents Chemother. 2003 Mar;47(3):1088-95. doi: 10.1128/AAC.47.3.1088-1095.2003.

Abstract

The pharmacodynamics of moxifloxacin against Streptococcus pneumoniae and Pseudomonas aeruginosa were investigated in a pharmacokinetic infection model. Three strains of S. pneumoniae, moxifloxacin, and two strains of P. aeruginosa were used. Antibacterial effect and emergence of resistance were measured for both species over a 72-h period using an initial inoculum of about 10(8) CFU/ml. At equivalent area under the curve (AUC)/MIC ratios, S. pneumoniae was cleared from the model while P. aeruginosa was not. For S. pneumoniae, the area under the bacterial kill curve up to 72 h could be related to AUC/MIC ratio using an inhibitory maximum effect (E(max)) model (concentration required for 50% E(max) [EC(50)], 45 +/- 22; r(2), 0.97). For P. aeruginosa even at the highest AUC/MIC ratio (427), bacterial clearance was insufficient for the EC(50) to be calculated. Emergence of resistance occurred with P. aeruginosa but not to any significant extent with S. pneumoniae. Emergence of resistance in P. aeruginosa as measured by population analysis profile (PAP-AUC) was dependent on drug exposure and time of exposure. In weighted least-squares regression analysis AUC/MIC ratio was predictive of PAP-AUC. When emergence of resistance was measured by the time for the colony counts on media containing antibiotic to increase by 2 logs, again AUC/MIC was the best predictor of emergence of resistance. However, for both experiments using S. pneumoniae and P. aeruginosa the correlation between all the pharmacodynamic parameters was high. These data indicate that for a given fluoroquinolone the magnitude of the AUC/MIC ratio for antibacterial effect is dependent on the bacterial species. Emergence of resistance is dependent on (i) species, (ii) duration of drug exposure, and (iii) drug exposure. A single AUC/MIC ratio magnitude is not adequate to predict antibacterial effect or emergence of resistance for all bacterial species.

摘要

在药代动力学感染模型中研究了莫西沙星对肺炎链球菌和铜绿假单胞菌的药效学。使用了三株肺炎链球菌、莫西沙星以及两株铜绿假单胞菌。使用约10(8) CFU/ml的初始接种量,在72小时内测定了两种菌的抗菌效果和耐药性的出现情况。在等效曲线下面积(AUC)/最低抑菌浓度(MIC)比值时,肺炎链球菌从模型中清除,而铜绿假单胞菌未被清除。对于肺炎链球菌,使用抑制最大效应(E(max))模型(达到50% E(max)所需浓度[EC(50)],45±22;r(2),0.97),直至72小时的细菌杀灭曲线下面积可与AUC/MIC比值相关。对于铜绿假单胞菌,即使在最高的AUC/MIC比值(427)时,细菌清除也不足以计算出EC(50)。铜绿假单胞菌出现了耐药性,但肺炎链球菌未出现明显耐药。通过群体分析谱(PAP-AUC)测定的铜绿假单胞菌耐药性的出现取决于药物暴露和暴露时间。在加权最小二乘回归分析中,AUC/MIC比值可预测PAP-AUC。当通过含抗生素培养基上菌落计数增加2个对数所需时间来测定耐药性出现时,AUC/MIC同样是耐药性出现的最佳预测指标。然而,对于使用肺炎链球菌和铜绿假单胞菌的两个实验,所有药效学参数之间的相关性都很高。这些数据表明,对于给定的氟喹诺酮类药物,抗菌效果的AUC/MIC比值大小取决于细菌种类。耐药性的出现取决于(i)细菌种类,(ii)药物暴露持续时间,以及(iii)药物暴露量。单一的AUC/MIC比值大小不足以预测所有细菌种类的抗菌效果或耐药性的出现。

相似文献

7
Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Antimicrob Agents Chemother. 2001 Mar;45(3):794-9. doi: 10.1128/AAC.45.3.794-799.2001.
9
Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
Antimicrob Agents Chemother. 2001 Oct;45(10):2916-21. doi: 10.1128/AAC.45.10.2916-2921.2001.

引用本文的文献

1
Dual Drug-Loaded Coaxial Nanofiber Dressings for the Treatment of Diabetic Foot Ulcer.
Int J Nanomedicine. 2024 Jun 11;19:5681-5703. doi: 10.2147/IJN.S460467. eCollection 2024.
2
Translational PK/PD for the Development of Novel Antibiotics-A Drug Developer's Perspective.
Antibiotics (Basel). 2024 Jan 11;13(1):72. doi: 10.3390/antibiotics13010072.
3
Individualising Therapy to Minimize Bacterial Multidrug Resistance.
Drugs. 2018 Apr;78(6):621-641. doi: 10.1007/s40265-018-0891-9.
4
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1183-93. doi: 10.1128/AAC.02177-15.
5
6
Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
Antimicrob Agents Chemother. 2015 Nov 9;60(1):515-21. doi: 10.1128/AAC.00727-15. Print 2016 Jan.
7
Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
Antimicrob Agents Chemother. 2013 Jun;57(6):2451-6. doi: 10.1128/AAC.01386-12. Epub 2013 Mar 4.
9
Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.
Antimicrob Agents Chemother. 2011 Apr;55(4):1436-42. doi: 10.1128/AAC.00936-10. Epub 2011 Jan 24.
10
Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
Antimicrob Agents Chemother. 2011 Feb;55(2):867-73. doi: 10.1128/AAC.00933-10. Epub 2010 Nov 15.

本文引用的文献

1
Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial.
Expert Opin Investig Drugs. 1999 Feb;8(2):181-99. doi: 10.1517/13543784.8.2.181.
2
Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
Antimicrob Agents Chemother. 2001 Oct;45(10):2916-21. doi: 10.1128/AAC.45.10.2916-2921.2001.
4
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
J Antimicrob Chemother. 2001 Jun;47(6):811-8. doi: 10.1093/jac/47.6.811.
5
Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2001 Jun;45(6):1654-9. doi: 10.1128/AAC.45.6.1654-1659.2001.
7
Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Antimicrob Agents Chemother. 2001 Mar;45(3):794-9. doi: 10.1128/AAC.45.3.794-799.2001.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验